Federal Agency for Medicines and Health Products (FAMHP) famhp.be

Tepkinly

Imported from official source

September 30, 2026 08:01 Announcement

Tepkinly Active substance Epcoritamab Holder AbbVie Belgium SA/NV Status Running Indication Epcoritamab in combination with lenalidomide and rituximab (R²) for the treatment of relapsed or refractory Follicular Lymphoma (FL), previously treated with at least 1 line of systemic chemoimmunotherapy (2L+). Public documents Approbation Information for the patient Informed consent Last update 30/09/2026 valerie.coqu Wed, 09/30/2026 - 10:14

Read the original at the source: https://www.famhp.be/fr/usage_humain/medicaments/medicaments/recherche_developpement/usage_compassionnel_programmes_133

Officially imported this from Federal Agency for Medicines and Health Products (FAMHP)’s own source. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.

Provenance

Organization: Federal Agency for Medicines and Health Products (FAMHP) — imported from official source
Official source: https://www.famhp.be/en/rss.xml RSS
Imported: October 03, 2026 20:37
Versions: 1 recorded
Identity: 110400 at https://www.famhp.be